|
|
H.-J. Böhm, G. Klebe and H. Kubinyi
Wirkstoffdesign Spektrum Akademischer Verlag, Heidelberg, 1996 (in German language) |
|
|
H. Kubinyi and G. Müller, Eds.,
Chemogenomics in Drug Discovery A Medicinal Chemistry Perspective Wiley-VCH, Weinheim, 2004 |
H. Kubinyi QSAR. Hansch Analysis and Related Approaches (Methods and Principles in Medicinal Chemstry, R. Mannhold, P. Kroogsgard- Larsen, and H. Timmerman, Eds., Vol. 1), VCH, Weinheim, 1993. H. Kubinyi, Ed. 3D QSAR in Drug Design. Theory, Methods and Applications, ESCOM, Science Publishers B.V., Leiden, 1993. H.-J. Böhm, G. Klebe and H. Kubinyi Wirkstoffdesign. Der Weg zum Arzneimittel, Spektrum Akademischer Verlag, Heidelberg, 1996. H. Kubinyi, G. Folkers and Y. C. Martin, Eds. 3D QSAR in Drug Design. Volume 2. Ligand-Protein Komplexes and Molecular Similarity, Kluwer / ESCOM, Dordrecht, 1998; also published in Persp. Drug Discov. Design 9-11 (1998). H. Kubinyi, G. Folkers and Y. C. Martin, Eds. 3D QSAR in Drug Design. Volume 3. Recent Advances, Kluwer/ ESCOM, Dordrecht, 1998; also published in Persp. Drug Discov. Design 12-14 (1998). H. Kubinyi and G. Müller, Eds. Chemogenomics in Drug Discovery - A Medicinal Chemistry Perspective (Volume 22 of Methods and Principles in Medicinal Chemistry, R. Mannhold, H. Kubinyi and G. Folkers, Eds.), Wiley-VCH, Weinheim, 2004. H. Kubinyi, Ed. Drug Discovery Technologies, Volume 3 of Comprehensive Medicinal Chemistry II, J. B. Taylor and D. J. Triggle, Eds., Elsevier, Oxford, 2007.
H. Kubinyi Isolierung, Struktur und Partialsynthese biologisch aktiver Naturstoffe aus Crotonöl, PhD Thesis, University of München, Germany, 1964. H. Kubinyi Lipophilie und biologische Aktivität: Ein Beitrag zu quantitativen Struktur-Wirkungsbeziehungen, Habilitation Thesis, University of Heidelberg, Germany, 1978.
A. Gloor, M. Cadisch, R. Bürgin Schaller, M. Farkas, T. Kocsis, J.T. Clerc, E. Pretsch, R. Aeschimann, M. Badertscher, T. Brodmeier, A. Fürst, H.-J. Hediger, M. Junghans, H. Kubinyi, M.E. Munk, H. Schriber, D. Wegmann SpecTool: A Hypermedia Book for Structure Elucidation of Organic Compounds with Spectroscopic Methods, Chemical Concepts, D-69442 Weinheim, 1994.
[1] E. Hecker, H. Kubinyi and H. Bresch Eine neue Gruppe von Cocarcinogenen aus Crotonöl, Angew. Chemie 76, 889 (1964); Angew. Chemie Internat. Edit. 3, 747 (1964). [2] E. Hecker and H. Kubinyi Über die Wirkstoffe des Crotonöls, IV: Reindarstellung und Charakterisierung der entzündlichen und cocarcinogenen Wirkstoffe B1 und B2, Z. Krebsforsch. 67, 176-191(1965). [3] E. Hecker, H. Kubinyi, H. U. Schairer, Ch. v. Szczepanski and H. Bresch Partialsynthese einiger cocarcinogener Wirkstoffe aus Crotonöl, Angew. Chemie 77, 1076 (1965); Angew. Chemie Internat. Edit. 4, 1072 (1965). [4] E. Hecker, H. Kubinyi, Ch. v. Szczepanski, E. Härle and H. Bresch Phorbol, ein neues tetracyclisches Diterpen aus Crotonöl, Tetrahedron Letters 1965, 1837-1842. [5] E. Hecker, H. Kubinyi, H. Bresch and Ch. v. Szczepanski The Chemical Structure of a Cocarcinogen and of Phorbol Isolated from Croton Oil, J. Med. Chem. 9, 246 (1966). [6] H. Bartsch, H. Bresch, M. Gschwendt, E. Härle, G. Kreibich, H. Kubinyi, H. U. Schairer, Ch. v. Szczepanski, H. W. Thielmann and E. Hecker Kombination wirksamer Trennverfahren mit modernen analytischen Methoden in der Naturstoffchemie. Isolierung und Struktur- aufklärung der biologisch aktiven Substanzen aus Crotonöl, Z. Anal. Chem. 221, 424-432 (1966). [7] E. Hecker, Ch. v. Szczepanski, H. Kubinyi, H. Bresch, E. Härle, H. U. Schairer and H. Bartsch Über die Wirkstoffe des Crotonöls, VII: Phorbol, Z. Naturforsch. 21b, 1204-1214 (1966). [8] E. Hecker, H. Bartsch, H. Bresch, M. Gschwendt, E. Härle, G. Kreibich, H. Kubinyi, H. U. Schairer, Ch. v. Szczepanski and H. W. Thielmann Structure and Stereochemistry of the Tetracyclic Diterpene Phorbol from Croton Tiglium L., Tetrahedron Letters 1967, 3165-3170. [9] H. Bresch, G. Kreibich, H. Kubinyi, H. U. Schairer, H. W. Thielmann and E. Hecker Über die Wirkstoffe des Crotonöls, IX: Partialsynthese von Wirkstoffen des Crotonöls, Z. Naturforsch. 23 b, 538-546 (1968). [10] K. Zechmeister, M. Röhrl, F. Brandl, S. Hechtfischer, W. Hoppe, E. Hecker, W. Adolf and H. Kubinyi Röntgenstrukturanalyse eines neuen makrozyclischen Diterpen- esters aus der Springwolfsmilch (Euphorbia lathyris L.), Tetrahedron Letters 1970, 3071-3073. [11] H. Kubinyi, B. Görlich and W. Steidle Acyl- und Alkylderivate des Proscillaridins, Planta Medica Suppl. 4, 127-131 (1971). [12] H. Kubinyi, W. Steidle and B. Görlich Proscillaridinacetate, Arch. Pharm. 304, 380-387 (1971). [13] H. Kubinyi, W. Steidle and B. Görlich Proscillaridin-3'-acylate, Arch. Pharm. 304, 430-436 (1971). [14] H. Kubinyi Proscillaridinmethyläther, Arch. Pharm. 304, 531-543 (1971). [15] H. Kubinyi Proscillaridincarbonate, Arch. Pharm. 304, 590-594 (1971). [16] H. Kubinyi Konformation der Rhamnose in Proscillaridin, Arch. Pharm. 304, 701-706 (1971). [17] H. Kubinyi, D. Hotz and W. Steidle Synthese eines Herzglykosids mit aromatischem Ring A, Liebigs Ann. Chem. 1973, 224-226. [18] H. Kubinyi and O.-H. Kehrhahn Quantitative Structure-Activity Relationships, 1. The Modified Free-Wilson Approach, J. Med. Chem. 19, 578-586 (1976). [19] H. Kubinyi Quantitative Structure-Activity Relationships, 2. A Mixed Approach, Based on Hansch and Free-Wilson Analysis, J. Med. Chem. 19, 587-600 (1976). [20] H. Kubinyi and O.-H. Kehrhahn Quantitative Structure-Activity Relationships, 3. A Comparison of Different Free-Wilson Models, J. Med. Chem. 19, 1040-1049 (1976). [21] H. Kubinyi Quantitative Structure-Activity Relationships, 4. Nonlinear dependence of biological activity on hydrophobic character: a new model, Arzneim.-Forsch. (Drug Res.) 26, 1991-1997 (1976). [22] H. Kubinyi Quantitative Structure-Activity Relationships, 5. A simple algorithm for Fujita-Ban and Free-Wilson analyses, Arzneim.- Forsch. (Drug Res.) 27, 750-758 (1977). [23] H. Kubinyi and O.-H. Kehrhahn Quantitative Structure-Activity Relationships, 6. Nonlinear dependence of biological activity on hydrophobic character: calculation procedures for the bilinear model, Arzneim.-Forsch. (Drug Res.) 28, 598-601 (1978). [24] H. Kubinyi Quantitative Structure-Activity Relationships, 7. The Bilinear Model, a New Model for Nonlinear Dependence of Biological Activity on Hydrophobic Character, J. Med. Chem. 20, 625-629 (1977) [25] H. Kubinyi Nonlinear Dependence of Biological Activity on Hydrophobic Character: The Bilinear Model, in Biological Activity and Chemical Structure, J. A. Keverling Buisman, Ed., Elsevier, Amsterdam, 1977, pp. 239-249. [26] H. Kubinyi Drug Partitioning: Relationships between the Forward and Reverse Rate Constants and the Partition Coefficient, J. Pharm. Sci. 67, 262-263 (1978). [27] H. Kubinyi Meproscillarin, ein neues halbsynthetisches Herzglykosid: Chemie und physikalische Eigenschaften, Arzneim.-Forsch. (Drug Res.) 28, 493-495 (1978). [28] H. Kubinyi Lipophilicity and Drug Activity, Prog. Drug. Res. 23, 97-198 (1979). [29] H. Kubinyi Nonlinear Dependence of Biological Activity on Hydrophobic Character: The Bilinear Model, Il Farmaco, Ed. Sci. 34, 248-276. (1979) [30] H. Kubinyi Lipophilicity and Biological Activity: Drug transport and drug distribution in model systems and in biological systems, Arzneim.-Forsch. (Drug Res.) 29, 1067-1080 (1979). [31] L. J. Schaad, B. A. Hess, Jr., W. P. Purcell, A. Cammarata, R. Franke and H. Kubinyi Compatibility of the Free-Wilson and Hansch Quantitative Structure-Activity Relations, J. Med. Chem. 24, 900-901 (1981). [32] H. Kubinyi Lipophilicity and Biological Activity: The Use of the Bilinear Model in QSAR, in QSAR in design of bioactive compounds (Proceedings of the First International Telesymposium on Medicinal Chemistry), M. Kuchar, Ed. J. R. Prous Science Publishers, Barcelona, 1984, pp. 321-346. [33] H. Kubinyi Theoretical and Practical Aspects of Quantitative Structure Activity Relationships, Acta Pharmac. Suec. Suppl. 1985:1, 255-267. [34] H. Kubinyi Quantitative Beziehungen zwischen chemischer Struktur und biologischer Aktivität, Chemie in unserer Zeit 20, 191-202 (1986). [35] H. Kubinyi Automatische Interpretation von Massenspektren, in 2. Workshop Software-Entwicklung in der Chemie, J. Gasteiger, Ed., Springer-Verlag, Heidelberg, 1988, pp. 167-179. [36] H. Kubinyi and G. Klebe Structure Activity Relationships of Calcium Antagonists, in: Actualidades de Química Terapéutica. Topics of Current Interest in Medicinal Chemistry, E. Raviña, Ed., University of Santiago de Compostela, Spanien, 1988, pp. 141-166. [37] H. Kubinyi Free Wilson Analysis. Theory, Applications and its Relationship to Hansch Analysis, Quant. Struct.-Act. Relat. 7, 121-133 (1988). [38] H. Kubinyi Current Problems in Quantitative Structure Activity Relationships, in: Physical Property Prediction in Organic Chemistry, C. Jochum, M. G. Hicks and J. Sunkel, Eds., Springer-Verlag, Heidelberg, 1988, pp. 235-247. [39] V. Schubert, W. Bremser, R. Neudert and H. Kubinyi Der Computer in der Massenspektrometrie, Nachr. Chem. Tech. Lab. 37, 720-728 (1989). [40] H. Kubinyi The Free Wilson Method and its Relationship to the Extrathermodynamic Approach, in Quantitative Drug Design, C. A. Ramsden, Ed., Vol. 4 of Comprehensive Medicinal Chemistry, C. Hansch, Ed., Pergamon Press, Oxford, 1990, pp. 589-643. [41] H. Kubinyi Quantitative structure-activity relationships (QSAR) and molecular modeling in cancer research, J. Cancer Res. Clin. Oncol. 116, 529-537 (1990). [42] H. Kubinyi Calculation of isotope distributions in mass spectrometry. A trivial solution for a non-trivial problem, Anal. Chim. Acta 247, 107-119 (1991). [43] H. Kubinyi Lipophilie und biologische Aktivität, Pharm. Ztg. Wiss. 136, 265-268 (1991). [44] H. Kubinyi The Third Dimension in QSAR: An Introduction, in: 3D QSAR in Drug Design. Theory, Methods and Applications, H. Kubinyi, Ed., ESCOM, Leiden, 1993, pp. 3-10. [45] H. Kubinyi and U. Abraham Practical Problems in PLS Analyses, in: 3D QSAR in Drug Design. Theory, Methods and Applications, H. Kubinyi, Ed., ESCOM, Leiden, 1993, pp. 717-728. [46] U. Thibaut, G. Folkers, G. Klebe, H. Kubinyi, A. Merz, and D. Rognan Recommendations for CoMFA Studies and 3D QSAR Publications, in: 3D QSAR in Drug Design. Theory, Methods and Applications, H. Kubinyi, Ed., ESCOM, Leiden, 1993, pp. 711-716. [47] U. Thibaut, G. Folkers, G. Klebe, H. Kubinyi, A. Merz, and D. Rognan Recommendations for CoMFA Studies and 3D QSAR Publications, Quant. Struct.-Act. Relat. 13, 1-3 (1994). [48] H. Kubinyi Der Schlüssel zum Schloß. I. Grundlagen der Arzneimittelwirkung, Pharmazie in unserer Zeit 23, 158-168 (1994). [49] H. Kubinyi Der Schlüssel zum Schloß. II. Hansch-Analyse, 3D-QSAR und De novo-Design, Pharmazie in unserer Zeit 23, 281-290 (1994). [50] H. Kubinyi Variable Selection in QSAR Studies. I. An Evolutionary Algorithm, Quant. Struct.-Act. Relat. 13, 285-294 (1994). [51] H. Kubinyi Variable Selection in QSAR Studies. II. A Highly Efficient Combination of Systematic Search and Evolution, Quant. Struct.- Act. Relat. 13, 393-401(1994). [52] H. Kubinyi The Quantitative Analysis of Structure-Activity Relationships, in: Burger´s Medicinal Chemstry and Drug Discovery, 5th Edition, Vol. I, Principles and Practice,M. E. Wolff, Ed., John Wiley & Sons, New York, 1995, pp. 497-571. [53] H. Kubinyi Spectrophotometric Analysis of Multicomponent Systems: The Law and the Error, Trends Anal. Chem. 14, 199-201 (1995). [54] H. Kubinyi Arzneimittel nach Maß, in: Moleküle nach Maß in der modernen Biotechnologie, Projektträger Biologie, Energie, Ökologie des Bundesministeriums für Bildung, Wissenschaft, Forschung und Technologie, Forschungszentrum Jülich GmbH, Jülich, 1995, pp. 71-76. [55] H. Kubinyi The Physicochemical Significance of Topological Parameters. A Rebuttal, Quant. Struct.-Act. Relat. 14, 149-150 (1995). [56] H. Kubinyi Lock and Key in the Real World. Concluding Remarks, Pharm. Acta Helv. 70, 259-269 (1995). [57] H. Kubinyi QSAR and Crystallography in Industrial Drug Design, in: Proceedings of the Workshop on Computer Aided Drug Design in Industrial Research, Ernst Schering Research Foundation-Workshop 15, R. Franke and C. Herrmann, Eds., Springer-Verlag Heidelberg, 1995, pp. 163-186. [58] H. Kubinyi Strategies and Recent Technologies in Drug Discovery, Pharmazie 50, 647-662 (1995). [59] H. Kubinyi From Lipophilicity to 3D QSAR - The Fascination of Computer-Aided Drug Design, in: Trends in QSAR and Molecular Modelling ´94 (Proceedings of the 10th European Symposium on Structure- Activity Relationships: QSAR and Molecular Modelling, F. Sanz, Eds., Prous Publishers, Barcelona, Spanien, 1995, pp. 2-16. [60] H. Kubinyi Variable Selection in QSAR Studies, in: Trends in QSAR and Molecular Modelling ´94 (Proceedings of the 10th European Symposium on Structure-Activity Relationships: QSAR and Molecular Modelling, F. Sanz, Ed., Prous Publishers, Barcelona, Spain, 1995, pp. 27-29. [61] H. Kubinyi Computer-Aided Drug Design: Facts and Fictions, in: Bioactive Compounds Design: Possibilities for Industrial Use", M. G. Ford, R. Greenwood, G. T. Brooks and R. Franke, Eds., BIOS Scientific Publishers Inc., Oxford, 1996, pp. 1-13. [62] H. Kubinyi Evolutionary Variable Selection in Regression and PLS Analyses, J. Chemometrics 10, 119-133 (1996). [63] H. Kubinyi A General View on Similarity and QSAR Studies, in: Computer- Assisted Lead Finding and Optimization (Proceedings of the 11th European Symposium on Quantitative Structure-Activity Relationships, Lausanne, 1996); van de Waterbeemd, H.; Testa, B.; Folkers, G., Eds.; Verlag Helvetica Chimica Acta and VCH: Basel, Weinheim, 1997; pp. 9-28. [64] H. van de Waterbeemd, R. E. Carter, G. Grassy, H. Kubinyi, Y. C. Martin, M. S. Tute and P. Willett Glossary of Terms Used in Computational Drug Design, Pure & Appl. Chem. 69, 1137-1152 (1997). [65] G. Folkers and H. Kubinyi Der gezielte Weg zum Arzneimittel, Spektrum der Wissenschaft, Spezial 6/97: Pharmaforschung, pp. 17-27 (1997); Vers un conception rationelle des médicaments, Pour la Science 241, 40-47 (Nov. 1997); Diseño racional de fármacos, Investigación y Ciencia 254, 32-41 (Nov. 1997; La progettazione razionale dei farmaci, Le Scienze quaderni 102, 8-14 (June 1998). [66] H. Kubinyi QSAR and 3D QSAR in Drug Design. I. Methodology, Drug Discovery Today 2, 457-467 (1997). [67] H. Kubinyi QSAR and 3D QSAR in Drug Design. II. Applications and Problems, Drug Discovery Today 2, 538-546 (1997). [68] H. Kubinyi Similarity and Dissimilarity - A Medicinal Chemist's View, in: 3D QSAR in Drug Design. Volume II. Ligand-Protein Interactions and Molecular Similarity, H. Kubinyi, G. Folkers and Y. C. Martin, Eds., Kluwer/ESCOM, Dordrecht, 1998, pp. 225-252; also published in: Persp. Drug Design Discov. 9-11, 225-252 (1998). [69] H. Kubinyi, F. A. Hamprecht and T. Mietzner Three-Dimensional Quantitative Similarity-Activity Relationships (3D QSiAR) from SEAL Similarity Matrices, J. Med. Chem. 41, 2553-2564 (1998). [70] H. Kubinyi Structure-based Design of Enzyme Inhibitors and Receptor Ligands, Curr. Opin. Drug Discov. Dev. 1, 4-15 (1998). [71] H. Kubinyi Combinatorial and Computational Approaches in Structure-based Drug Design, Curr. Opin. Drug Discov. Dev. 1, 16-27 (1998). [72] H. Kubinyi Molekulare Ähnlichkeit. 1. Chemische Struktur und biologische Wirkung, Pharmazie in unserer Zeit 27, 92-106 (1998). [73] H. Kubinyi Molekulare Ähnlichkeit. 2. Strukturbasierter Entwurf von Wirkstoffen, Pharmazie in unserer Zeit 27, 158-172 (1998). [74] J. Sadowski and H. Kubinyi. A Scoring Scheme for Discriminating Between Drugs and Non-Drugs, J. Med. Chem. 41, 3325-3329 (1998). [75] H. Kubinyi Comparative Molecular Field Analysis (CoMFA), in: The Encyclopedia of Computational Chemistry, Vol. 1, Schleyer, P. v. R., Allinger, N. L., Clark, T., Gasteiger, J., Kollman, P. A., Schaefer III, H. F., and Schreiner, P. R., Eds.; John Wiley & Sons, Chichester, 1998, pp. 448-460. [76] H. Kubinyi Quantitative Structure-Activity Relationships in Drug Design, in: The Encyclopedia of Computational Chemistry, Vol. 4, Schleyer, P. v. R., Allinger, N. L., Clark, T., Gasteiger, J., Kollman, P. A., Schaefer III, H. F., and Schreiner, P. R., Eds.; John Wiley & Sons, Chichester, 1998, pp. 2309-2320. [77] H. Kubinyi Structure-based Drug Design, Chimica Oggi / Chemistry Today 16(10), 17-22 (1998). [78] H. Kubinyi Chance Favors the Prepared Mind. From Serendipity to Rational Drug Design, J. Receptor & Signal Transduction Research 19, 15-39 (1999). [79] H. Kubinyi Combinatorial Chemistry: Novel Strategies, Chemistry, Purification, and Chemoinformatics, Drug & Market Development 10, 360-365 (1999). [80] H. Kubinyi Kombinatorische Chemie (1). Aufbruch in ein neues Zeitalter, Chemie heute - Das Wissenschaftsmagazin des Fonds der Chemischen Industrie, Edition 1999/2000, pp. 14-16. [81] H. Kubinyi Zwischen Zufall und Entwurf. Arzneimittelsuche mit Hilfe der Kombinatorischen Chemie, Kultur & Technik, Zeitschrift des Deutschen Museums, 2/2000, 10-15. [82] H. Kubinyi Arzneimittel - Vom glücklichen Zufall zum gezielten Entwurf, in: Die Innere Medizin an der Schwelle des neuen Jahrhunderts. Forschungsperspektiven in den Schwerpunktfächern und flankierenden Disziplinen, J. R. Kalden, H. Klinger and D. Welzel, Eds., Schattauer, Stuttgart, 2000, pp. 149-164. [83] H. Kubinyi Hydrogen Bonding, the Last Mystery in Drug Design? in: Pharmacokinetic Optimization in Drug Research. Biological, Physicochemical, and Computational Strategies, B. Testa, H. van de Waterbeemd, G. Folkers and R. Guy, Eds., Helvetica Chimica Acta and Wiley-VCH, Zürich, 2001, pp. 513-524. [84] H. Kubinyi Computational Approaches in Rational Drug Design, Chimie nouvelle 73, 3238-3239 (2001). [85] H. Kubinyi Der Wandel in der Arzneimittelforschung. Vom glücklichen Zufall zum gezielten Entwurf, Forschung für Leben, Nr. 59, Zurich, April 2001. [86] H. Kubinyi Similarity and Biological Activities, BIOforum 5(3), 130-131 (2001). [87] H. Kubinyi Random vs. Rational Drug Discovery (Editorial), Curr. Drug Discov., Oct. 2001, 9-11. [88] H. Kubinyi The Design of Combinatorial Libraries, Drug Discovery Today 7, 503-504 (2002). [89] H. Kubinyi High Throughput in Drug Discovery, Drug Discovery Today 7, 707-709 (2002). [90] H. Kubinyi From Narcosis to Hyperspace: The History of QSAR, Quant. Struct.-Act. Relat. 21, 348-356 (2002). [91] H. Kubinyi Chemical Similarity and Biological Activities, J. Braz. Chem. Soc. 13, 717-726 (2002). [92] H. Kubinyi Drug Research: Myths, Hype and Reality, Nature Rev. Drug Discov. 2, 665-668 (2003). [93] H. Kubinyi QSAR in Drug Design, in: Handbook of Chemoinformatics. From Data to Knowledge, Volume 4, J. Gasteiger, Ed., Wiley-VCH, Weinheim, 2003, pp. 1532-1554. [94] H. Kubinyi Comparative Molecular Field Analysis (CoMFA), in: Handbook of Chemoinformatics. From Data to Knowledge, Volume 4, J. Gasteiger, Ed., Wiley-VCH, Weinheim, 2003, pp. 1555-1574. [95] H. Kubinyi In Search for New Leads, EFMC - Yearbook 2003, pp. 14-28; also published in Rossiiskii Khimicheskii Zhurnal 50(2), 5-17 (2006) (in Russian language). [96] H. Kubinyi 2D QSAR Models: Hansch and Free Wilson Analyses, in: Computational Medicinal Chemistry for Drug Discovery, P. Bultinck, H. De Winter, W. Langenaeker and J. P. Tollenaere, Eds., Dekker Inc., New York, 2003, pp. 539-570. [97] H. Kubinyi The Evolution of Drugs, Med. Chem. Res. 13, 5-6 (2004). [98] H. Kubinyi In Search for New Leads, Industrial Pharmacy, March 2004, pp. 7-10. [99] H. Kubinyi Drugs from side effects, in: H. Kubinyi and G. Müller, Eds., Chemogenomics in Drug Discovery - A Medicinal Chemistry Perspective (Volume 22 of Methods and Principles in Medicinal Chemistry, R. Mannhold, H. Kubinyi and G. Folkers, Eds.), Wiley-VCH, Weinheim, 2004, pp. 43-67. [100] H. Kubinyi Changing Paradigms in Drug Discovery, in: The Chemical Theatre of Biological Systems (Proceedings of the International Beilstein Workshop, Bozen, Italy, May 24-28, 2004), M. Hicks and C. Kettner, Eds., Logos-Verlag, Berlin, 2005, pp. 51-72. Reprint in: Modelling Molecular Structure and Reactivity in Biological Systems, K. J. Naidoo, J. Brady, M. J. Field, J. Gao and M. Hann, Eds. (RSC Publishing No. 304), The Royal Society of Chemistry, Cambridge, 2006, pp. 219-232. [101] H. Kubinyi Privileged Structures and Analogue-Based Drug Discovery, in: Analogue-based Drug Discovery, IUPAC, J. Fischer, and C. R. Ganellin, Eds., Wiley-VCH, Weinheim, 2006, pp. 53-68. [102] H. Kubinyi Validation and Predictivity of QSAR Models, in: QSAR & Molecular Modelling in Rational Design of Bioactive Molecules (Proceedings of the 15th European Symposium on QSAR & Molecular Modelling, Istanbul, Turkey, 2004), E. Aki Sener and I. Yalcin, Eds., CADDD Society, Ankara, Turkey, 2006, pp. 30-33. [103] H. Kubinyi Chemogenomics in Drug Discovery, Ernst Schering Research Foundation Workshop 58, "Chemical Genomics. Small Molecule Probes to Study Cellular Function", S. Jaroch and H.Weinmann, Eds., Springer, Berlin, 2006, pp. 1-19. [104] H. Kubinyi Success Stories of Computer-Aided Design, in: Computer Applications in Pharmaceutical Research and Development, S. Ekins, Ed. (Wiley Series in Drug Discovery and Development, B. Wang, Ed.), Wiley-Interscience, New York, 2006, pp. 377-424. [105] F. Darvas, O. Kappe, G. Schneider, M. Wiese and H. Kubinyi QSAR/QSPR Modelling - Finding Rules in Noisy Data? QSAR Comb. Sci. 25, 811-812 (2006). [106] H. Kubinyi Leitstrukturen - der Start zum Arzneimittel, Österr. Apoth.-Ztg. 60, 1112-1115 (2006). [107] H. Kubinyi The Drug Discovery Process, in: Wiley Handbook of Current and Emerging Drug Therapies, John Wiley & Sons, Hoboken, NJ, 2006, pp. 3-23. [108] H. Kubinyi Techniques for Rational Design, Drug Discovery Today: Technologies 3, 423-424 (2006). [109] H. Kubinyi Chemogenomics in Drug Discovery, in: Drug Discovery Technologies, H. Kubinyi, Ed., Volume 3 of Comprehensive Medicinal Chemistry II, J. B. Taylor and D. J. Triggle, Eds., Elsevier, Oxford, 2007, pp. 921-937. [110] H. Kubinyi The Changing Landscape in Drug Discovery, in: Computational Approaches to Structure Based Drug Design, R. M. Stroud, Ed., Royal Society of Chemistry, London, 2007, pp. 24-45. [111] H. Kubinyi Arzneimittel, die uns fast nicht erreichten, in: E. Kut and M. Schmid (Eds.), Heilen - Gesunden, Das andere Arzneibuch, Festschrift zum 60. Geburtstag von Gerd Folkers, Edition Collegium Helveticum, Volume 9, Collegium Helveticum, Zürich 2013; pp. 29-32.
Home
Zurück zur Startseite